Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC : Episode 7
CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC
Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.
EP: 1.The State of Targeted Therapies in NSCLC
EP: 2.Frontline Treatments for KRAS G12C-Mutation mNSCLC
EP: 3.Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations
EP: 4.The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC
EP: 5.Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition
EP: 6.Disease Progression Beyond Frontline KRAS G12C Inhibitors
Now Viewing
EP: 7.CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC
EP: 8.KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC
EP: 9.Practical Management of Hepatotoxicity in KRAS G12C Inhibitors
EP: 10.Future Perspectives in KRAS G12C-Mutated NSCLC
Related Videos
Related Content
